Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

SRP3160

Sigma-Aldrich

sRank Receptor human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Synonyme(s) :

ODAR (osteoclast differentiation and activation receptor), TNFRSF11A, TRANCE Receptor

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352200
Nomenclature NACRES :
NA.32

Source biologique

human

Produit recombinant

expressed in E. coli

Pureté

≥98% (HPLC)
≥98% (SDS-PAGE)

Forme

lyophilized

Puissance

30-50 ng/mL ED50

Poids mol.

19.3 kDa

Conditionnement

pkg of 100 μg

Technique(s)

cell culture | mammalian: suitable

Impuretés

<0.1 EU/μg endotoxin, tested

Couleur

white

Numéro d'accès UniProt

Conditions d'expédition

wet ice

Température de stockage

−20°C

Informations sur le gène

Description générale

Soluble receptor activator of nuclear factor-κB (sRANK) also known as TNF receptor superfamily member 11a (TNFRSF11A), is encoded by the gene mapped to human chromosome 18. The encoded protein belongs to the tumor necrosis factor (TNF) receptor superfamily. RANK is widely expressed in variety of tissues, including skeletal muscle, thymus, liver, colon, small intestine, adrenal gland, osteoclast, mammary gland epithelial cells, prostate and pancreas. Recombinant human sRANK receptor is a 19.3kDa polypeptide containing the TNFR homologous cysteine rich portion of the extracellular domain of RANK receptor (175 amino acid residues).

Actions biochimiques/physiologiques

Soluble receptor activator of nuclear factor-κB (sRANK) plays a vital role in bone remodeling and fracture repair. Alterations in the RANK signaling increase the risk of susceptibility to expansile osteolysis and Paget disease of bone (PDB2). In addition, mutation of the gene coding for RANK/RANKL/OPG has also been observed in various skeletal disorders such as osteoporosis, glucocorticoid-induced bone loss, multiple myeloma, and rheumatoid arthritis. Binding of RANKL to its receptor RANK triggers the formation and differentiation of osteoclasts with the help of various transcription factors involved in modulation of osteoclastogenesis. RANK/RANKL/OPG might act as a potent therapeutic target for bone diseases.

Séquence

MQIAPPCTSE KHYEHLGRCC NKCEPGKYMS SKCTTTSDSV CLPCGPDEYL DSWNEEDKCL LHKVCDTGKA LVAVVAGNST TPRRCACTAG YHWSQDCECC RRNTECAPGL GAQHPLQLNK DTVCKPCLAG YFSDAFSSTD KCRPWTNCTF LGKRVEHHGT EKSDAVCSSS LPARK

Forme physique

Lyophilized from 10 mM Sodium Phosphate, pH 7.2.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.
Hughes AE
Nature Genetics, 24(1), 45-48 (2000)
Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.
Colombini A
International Orthopaedics, 35(5), 777-782 (2011)
RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T
Trends in Molecular Medicine, 12(1), 17-25 (2006)
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D
The Journal of Clinical Endocrinology and Metabolism, 92(12), 4514-4521 (2007)
H Hsu et al.
Proceedings of the National Academy of Sciences of the United States of America, 96(7), 3540-3545 (1999-03-31)
A receptor that mediates osteoprotegerin ligand (OPGL)-induced osteoclast differentiation and activation has been identified via genomic analysis of a primary osteoclast precursor cell cDNA library and is identical to the tumor necrosis factor receptor (TNFR) family member RANK. The RANK

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique